Top-News
Pharmazeutika USA

Ionis Pharmaceuticals Inc News

Aktie
WKN:  A2ACMZ ISIN:  US4622221004 US-Symbol:  IONS
35,85 €
-0,49 €
-1,35%
20:43:12 Uhr
Handeln Depot/Watchlist
Aktienanzahl *
145,75 Mio.
Marktkapitalisierung *
5,29 Mrd. €
Streubesitz
-
Index-Zugehörigkeit
Nasdaq Composite Index
IR-Website
zur Website
*Stand: 11.03.2024
Weiter abwärts? Short handeln - Jetzt mit Hebel 6,51: ME9278

Ionis Pharmaceuticals Inc News

18.12.23 - PR Newswire
Ionis announces European licensing agreement with Otsuka for donidalorsen in hereditary angioedema
Ionis announces European licensing agreement with Otsuka for donidalorsen in hereditary angioedema PR Newswire
14.12.23 - PR Newswire
Ionis announces the appointment of Michael Yang to Board of Directors
Ionis announces the appointment of Michael Yang to Board of Directors PR Newswire
11.11.23 - PR Newswire
Ionis shares positive clinical update from ongoing trial of ION582 for Angelman syndrome
Ionis shares positive clinical update from ongoing trial of ION582 for Angelman syndrome PR Newswire
09.11.23 - PR Newswire
Ionis presents positive two-year results from the Phase 2 open label extension study of donidalorsen in patients with hereditary angioedema
Ionis presents positive two-year results from the Phase 2 open label extension study of donidalorsen in patients with hereditary angioedema PR Newswire
03.11.23 - PR Newswire
Ionis to present at upcoming investor conferences
Ionis to present at upcoming investor conferences PR Newswire
02.11.23 - 4investors
Ionis Pharmaceuticals: Beteiligung von BB Biotech meldet Zahlen
02.11.23 - PR Newswire
Ionis reports third quarter 2023 financial results
Ionis reports third quarter 2023 financial results PR Newswire
19.10.23 - PR Newswire
Ionis to hold third quarter 2023 financial results webcast
Ionis to hold third quarter 2023 financial results webcast PR Newswire
04.10.23 - PR Newswire
Ionis shares significant business and pipeline progress at Innovation Day, highlighting strength of capabilities from research and technology through commercialization
Ionis shares significant business and pipeline progress at Innovation Day, highlighting strength of capabilities from research and technology through commercialization PR Newswire
28.09.23 - PR Newswire
Eplontersen Phase 3 results published in JAMA show consistent and sustained benefit
Eplontersen Phase 3 results published in JAMA show consistent and sustained benefit PR Newswire
27.09.23 - 4investors
Ionis Pharmaceuticals vertieft Partnerschaft mit Roche
27.09.23 - PR Newswire
Ionis enters agreement with Roche for two novel RNA-targeted programs for Alzheimer's disease and Huntington's disease
Ionis enters agreement with Roche for two novel RNA-​targeted programs for Alzheimer's disease and Huntington's disease PR Newswire
26.09.23 - PR Newswire
Ionis announces positive olezarsen topline results from Phase 3 study in people with familial chylomicronemia syndrome
Ionis announces positive olezarsen topline results from Phase 3 study in people with familial chylomicronemia syndrome PR Newswire
12.09.23 - PR Newswire
Ionis to host investor and analyst day event
Ionis to host investor and analyst day event PR Newswire
30.08.23 - PR Newswire
Ionis to present at upcoming investor conferences
Ionis to present at upcoming investor conferences PR Newswire
09.08.23 - Der Aktionär
Ionis Pharmaceuticals: AKTIONÄR‑Tipp startet durch – das steckt dahinter
09.08.23 - PR Newswire
Ionis reports second quarter 2023 financial results
Ionis reports second quarter 2023 financial results PR Newswire
03.08.23 - PR Newswire
Ionis enters collaboration to advance next generation program targeting Lp(a) for cardiovascular disease
Ionis enters collaboration to advance next generation program targeting Lp(a) for cardiovascular disease PR Newswire
01.08.23 - Der Aktionär
AKTIONÄR‑Pharma Tipp – „Zeit zu kaufen“
28.07.23 - PR Newswire
Ionis expands eplontersen agreement with AstraZeneca to include exclusive rights in Latin America
Ionis expands eplontersen agreement with AstraZeneca to include exclusive rights in Latin America PR Newswire

Newssuche

Videos

07.05.24 -4,91%
Technical Trading: DAX Long kurzfristig
DAX Long Typ: Turbo Open End WKN: NG8K9X Hebel: 26 Laufzeit: OpenEnd Einstieg: Market ... Mehr »